Cara Therapeutics shares are trading higher by 15% during Thursday's session. The company earlier announced it engaged Piper Sandler & Co. as a financial advisor to explore strategic alternatives. See ...
Cara Therapeutics (NASDAQ:CARA) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of ...
Cara Therapeutics said its Notalgia Paresthetica drug failed in clinical trials. The company is looking at strategic alternatives. Get daily-updated rankings across momentum, growth, value, trends, ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An update from Cara Therapeutics ( ...
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. , a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients ...
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi. Click here to learn how ...
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Cara Therapeutics (CARA – Research Report), with a price target of $5.00. Joseph Stringer has given his Buy rating ...
Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter Financial Results and Update conference call. All ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results